iiinova — where your digital self keeps evolving

Geert Bultynck / LMCSLeuven @lmcsleuven.bsky.social · 27/07/2026

Our collaborative study on mechanisms of venetoclax resistance by BCL-2 mutations is now published in #Advanced #Science journal. Please check LinkedIn for a more detailed explanation and gratitude to all contributors, collaborators and funders. advanced.onlinelibrary.wiley.com/doi/10.1002/...

advanced.onlinelibrary.wiley.com

Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance

Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL-2 variants. G101V and D103Y reduce d...

110

Geert Bultynck / LMCSLeuven @lmcsleuven.bsky.social · 23/02/2026

Anti-apoptotic BCL-2 binds to all three IP3R isoforms, thereby limiting the Ca2+-flux properties of IP3R homo-tetramers url: royalsocietypublishing.org/rsob/article.... Great work from Ian de Ridder,Claire Cauwelier, Jens Loncke and fantastic collaborators from David Yule and Irina Serysheva teams!

royalsocietypublishing.org

Anti-apoptotic BCL-2 binds to all three IP3R isoforms, thereby limiting the Ca2+-flux properties of IP3R homo-tetramers

Abstract. Anti-apoptotic B-cell lymphoma 2 (BCL-2) controls inositol 1,4,5-trisphosphate receptor (IP3R)-mediated Ca²+ signalling. As cells typically expre

010

Geert Bultynck / LMCSLeuven @lmcsleuven.bsky.social · 21/03/2025

www.nature.com/articles/s41... or how Apoptosis control by BCL2-family targeting can tackle a plethora of human diseases! A review coordinated by Meike Vogler togetherwith international consortium! 🙏 for opportunity to contribute explaining #calcium #signaling & implications for #neurodegenration!

nature.com

The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy - Signal Transduction and Targeted Therapy

Signal Transduction and Targeted Therapy - The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy

010